BioSavita

About:

BioSavita's high throughput synthetic DNA technologies and yeast strains enable the rapid manufacture of fully functional antibodies,

Website: http://biosavita.com/

Description:

BioSavita's high throughput synthetic DNA technologies and yeast strains enable the rapid manufacture of fully functional antibodies, single domain antibodies, antibody-drug conjugates and fusion proteins. They are focused on developing novel biological drugs and vaccines in partnership with biopharmaceutical companies and government agencies.

Total Funding Amount:

$3M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Plymouth, Michigan, United States

Founded Date:

1994-06-01

Founders:

Nalini Motwani

Number of Employees:

1-10

Last Funding Date:

2014-10-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai